The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer

Bredin, Philip; Naidoo, Jarushka

doi:10.1007/s10555-022-10039-1

Cited by 14 publications

(11 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is known that the microbiome plays an important role in human health and disease by modulating a host's innate and adaptive immune system, immune responses, and metabolism, and by protecting from invading pathogens [235][236][237]. The tumor microenvironment (TME) influences cancer progression and therapy responses [238] and many recent studies have demonstrated associations between the TME and microbiota composition and responses to immune checkpoint inhibitors in cancer patients, including NSCLC patients, suggesting that modulation of the microbiota through diet, probiotics, and fecal microbiota transplantations (FMT) could improve treatment efficacy [238][239][240][241][242][243][244]. There is also a possibility that the lung microbiome change could be used as a biomarker for detecting clinical phenotypes [245].…”

Section: Microbiomementioning

confidence: 99%

Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis

Souza

Forder²,

Brockley³

et al. 2023

IJMS

View full text Add to dashboard Cite

Liquid biopsies have emerged as a promising tool for the detection of metastases as well as local and regional recurrence in lung cancer. Liquid biopsy tests involve analyzing a patient’s blood, urine, or other body fluids for the detection of biomarkers, including circulating tumor cells or tumor-derived DNA/RNA that have been shed into the bloodstream. Studies have shown that liquid biopsies can detect lung cancer metastases with high accuracy and sensitivity, even before they are visible on imaging scans. Such tests are valuable for early intervention and personalized treatment, aiming to improve patient outcomes. Liquid biopsies are also minimally invasive compared to traditional tissue biopsies, which require the removal of a sample of the tumor for further analysis. This makes liquid biopsies a more convenient and less risky option for patients, particularly those who are not good candidates for invasive procedures due to other medical conditions. While liquid biopsies for lung cancer metastases and relapse are still being developed and validated, they hold great promise for improving the detection and treatment of this deadly disease. Herein, we summarize available and novel approaches to liquid biopsy tests for lung cancer metastases and recurrence detection and describe their applications in clinical practice.

show abstract

Section: Microbiomementioning

confidence: 99%

Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis

Souza

Forder²,

Brockley³

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…There are many current related clinical studies on this subject. 23,[46][47][48] A Phase I clinical trial on pembrolizumab combined with anti-LAG-3 antibody favezelimab in 89 previously treated MSS mCRC patients showed four patients with partial remission and one patient achieving complete remission. The median remission duration was 10.6 months and the toxicity was controllable, suggesting that combined immunotherapy may have survival benefits in patients with MSS type cancer.…”

Section: Other Immune Checkpoint Moleculesmentioning

confidence: 99%

Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

Li¹,

Xu²

2023

IJGM

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common diseases in the world. Tumor immunotherapy is an innovative cancer treatment that acts by activating the human body's autoimmune system. Immune checkpoint block has been shown to be effective in DNA deficient mismatch repair/microsatellite instability-high CRC. However, the therapeutic effect for proficient mismatch repair/ microsatellite stability patients still requires further study and optimization. At present, the main CRC strategy is to combine other therapeutic methods, such as chemotherapy, targeted therapy, and radiotherapy. Here, we review the current status and the latest progress of immune checkpoint inhibitors in the treatment of CRC. At the same time, we consider therapeutic opportunities for transforming cold to hot, as well as perspectives on possible future therapies, which may be in great demand for drug-resistant patients.

show abstract

“…Moreover, adaptive immune resistance is observed in lung cancer patients and attenuated the immunotherapeutic benefits ( Gkountakos et al, 2021 ; Gemelli et al, 2022 ). Furthermore, immunotherapy often causes side-effects, such as endocrinopathy, colitis, pneumonitis, nephritis in lung cancer patients ( Bredin and Naidoo, 2022 ; Hao et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Wang

Zhu²,

Yang³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.

show abstract

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer

Cited by 14 publications

References 130 publications

Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis

Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis

Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Contact Info

Product

Resources

About